PROGRAMME AT A GLANCE

Similar documents
Autoimmune Hepatitis Events Easl

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC

Transplant Hepatology

Life After SVR for Cirrhotic HCV

Clinical Trials & Endpoints in NASH Cirrhosis

4th UpDate on Hepatology

During the course of the 12 month fellowship, candidates will attend at least one international liver meeting (generally AASLD).

Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?

Overall Goals and Objectives for Transplant Hepatology EPAs:

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?

Dr. Siddharth Srivastava

HEPAMAP: A ROADMAP FOR HEPATOLOGY RESEARCH IN EUROPE: AN OVERVIEW FOR POLICY MAKERS

MINI PROGRAMME SEE YOU NEXT YEAR IN LONDON APRIL 2020

Hepatitis C Update on New Treatments

EVALUATION OF ABNORMAL LIVER TESTS

Index. Note: Page numbers of article titles are in boldface type.

Preliminary Program Outline

CAPGAN th Scientific Meeting of Commonwealth Association of Paediatric, Gastroenterology and Nutrition 2-4 October 2015 : New Delhi, India

ABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust

Gastroenterology. Certification Examination Blueprint. Purpose of the exam

Hepatitis. Dr. Mohamed. A. Mahdi 5/2/2019. Mob:

Day-at-a-Glance. Saturday, June 2, 2018

Hepatocellular Carcinoma: Diagnosis and Management

The 10th Congress of the Jordanian Society of Gastroenterology & Hepatology

The impact of the treatment of HCV in developing Hepatocellular Carcinoma

HCV care after cure. This program is supported by educational grants from

Western Health Specialist Clinics Access & Referral Guidelines

2017 Canadian Association of Gastroenterology Educational Needs Assessment Report

FRIDAY, MARCH 9 SUNDAY, MARCH

Assessing the patient with a new diagnosis of Hepatitis C LAUREN MYERS MMSC, PA-C OREGON HEALTH & SCIENCE UNIVERSITY

Management of Hepatitis B - Information for primary care providers

The Role of Liver Societies in the Global Viral Hepatitis Response

Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition

HEPATOCELLULAR CARCINOMA: AN OVERVIEW

5th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow

NEURO- GASTRO- ENTEROLOGY & MOTILITY OESO- PHAGUS LOGY. Room A Room B Room C Room E1 Room E2 Room M Room N1 Room N2 Room L8 Room 1.

Hepatology for the Nonhepatologist

Surveillance for Hepatocellular Carcinoma

The Role of Liver Societies in the Global Viral Hepatitis Response

Liver disease in 2017: challenges and opportunities

Steps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV

A Review of Liver Function Tests. James Gray Gastroenterology Vancouver

Liver Transplantation Evaluation: Objectives

Cornerstones of Hepatitis B: Past, Present and Future

SCIENTIFIC PROGRAMME

GASTROENTEROLOGY Maintenance of Certification (MOC) Examination Blueprint

ELPA S VISION OF SCREENING

Worldwide Causes of HCC

Hepatology For The Nonhepatologist

CIRROSI E IPERTENSIONE PORTALE NELLA DONNA

Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?

Liver Failure. The most severe clinical consequence of liver disease is liver failure:

Hepatocellular Carcinoma (HCC)

Index. Note: Page numbers of article titles are in boldface type.

LIVER DISEASE WRAP-UP

Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O.

Management of Patients with Chronic Hepatitis B: The Alaska Experience

Hepatitis C: How sick can we treat? Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of

Viral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg

34TH. New Treatments in Chronic Liver Disease. MAIN CONFERENCE: MARCH 9 10, 2019 Pre-Conference: March 8, 2019 Estancia La Jolla La Jolla, California

Role of Liver Biopsy. Role of Liver Biopsy 9/3/2009. Liver Biopsies in Viral Hepatitis: Beyond Grading and Staging

Hepatocellular Carcinoma. Markus Heim Basel

Tumor incidence varies significantly, depending on geographical location.

Esophageal Varices Beta-Blockers or Band Ligation. Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph

Hepatocellular carcinoma

Investigations before OLT, Immunosuppression and rejection, Follow up after OLT.

The Sheila Sherlock Royal Free Hepatology Postgraduate Course Date: 15 th 17 th May 2019 Location: Royal Free Hospital, London, United Kingdom

Supplementary Digital Content

Hepatitis C Policy Discussion

Screening for HCCwho,

PREVALENCE OF NAFLD & NASH

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

Initial Evaluation for HCV Therapy. Hope McGratty PA-C, MPH

How to Approach a Medical Liver Biopsy. 9 th Bryan Warren School of Pathology Pancreatic and Liver Pathology. Sarajevo, 6 th -7 th November 2015

NHIVNA Pre-conference Study Day Current Issues in HIV, Hepatitis and other Blood-borne Viruses In collaboration with BASLNF

FATTY LIVER DISEASE (NAFLD) (NASH) A GROWING

STOP Hepatocellular Carcinoma

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

The subject is composed from theoretical lectures and clinical practicals.

Liver Disease in Cystic Fibrosis

HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT

DAA-based treatment in cirrhotic and post-transplanted patients. Audrey Coilly, MD Hôpital Paul Brousse, Villejuif, France

THURSDAY, SEPTEMBER 20 TH

HCC: Is it an oncological disease? - No

Lahey Clinic Internal Medicine Residency Program: Curriculum for Gastroenterology

Learning Objectives. After attending this presentation, participants will be able to:

The place of bariatric surgery in NASH: can we extend the indications? - No

FRIDAY, MARCH 31 SUNDAY, APRIL

Evaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA

Hepatocellular carcinoma in Sri Lanka - where do we stand?

6 Riunione Monotematica A.I.S.F NASH malattia epatica, oncologica e cardiovascolare

Jose D Sollano, MD Professor of Medicine University of Santo Tomas Manila, Philippines. University of Santo Tomas

New York State HCV Provider Webinar Series. Side Effects of Therapy

Gastrointestinal System: Accessory Organ Disorders

Changing epidemiology of HCC in Italy

Transcription:

PROGRAMME AT A GLANCE Hotel Hyatt Andaz Hotel Pullman Date Hall-H1 Hall-H2 Hall-P1 Hall-P2 Hall-P3 Hall-P4 Hall-P5 Hall-P6 Basic science workshop 1 Basic Science Workshop 2 Postgraduate Course - Liver Transplant Theme : Liver Transplant APASL- AASLD Clinical Research Methodology Workshop Day to Day Challenges 08:30 10:30 08:00-09:30 Session 1: Regenerative Session 1:LDLT in difficult Medicine: Cells to Organsituations 1 08:05-10:10 Session 1: Observational Studies 10:50-11:15 09:30-10:30 Session 2: Immunosuppression for Liver Transplantation 10:10-10:30 11:15-12:55 Session 1: Regenerative Medicine: Cells to Organ- 2 10:30-11:00 10:30-12:35 Session 2: Experimental studies 14-Mar-18 13:00-14:30 11:00-12:30 Session 3: Transplant Grand Rounds-Cases [mentor and mentee] 12:35-13:35 Session 3: Plenary Session 14:30-16:45 Session 2: Advanced tools of cytoanalysis 12:30-13:30 Session 4: Post liver transplant radiology and pathology 13:35-14:20 16:45-17:00 13:30-14:30 14:20-16:20 Session 4: Break out Room A

Session 5: Perioperative management of liver 17:00-18:25 transplant patient Session 3: Lipid, Bile acids and iron trafficking in homeostatic and disease physiology 16:00-16:15 14:20-16:20 Session 4: Break out Room A Editor Forum 16:30-17:30 What do the Editors look for in manuscript for decision making? Main PG course Workshop: Experimental models of liver 15 th March, 08:00-09:45 Session 1: Viral Hepatitis: Difficult Treatment Decisions 09:45-11:15 Session 2: Alcoholic Liver Disease and Non-alcoholic fatty Liver Disease 08:00-10:10 Workshop Session 1: 11:00-11:20 11:20-12:10 Session 3: Alcoholic Liver Disease 12:10-13:30 Session 4: Challenges in Hepatology 11:20-13:20 Workshop Session 2: 15th March, 13:30-14:30 symposia Session 5: Prescriptions in Liver Diseases 15:45-17:00 Session 6: Complications of Cirrhosis Workshop Session 3: 16:00-17:00 Workshop Session 4: Session 7: Liver Failure CEVHAP Symposium: Partnerships in Action Faculty Dinner

16 th March, Pediatric hepatology Critical Care Heptology Oral papers Oral papers Oral papers 08:00-09:40 Session 1: Viral Hepatitis B- HepatitisSession: 1 APASL-ISHEN Session 1: APASL -IAC new challenges session: Hepatic Encephalopathy-Hepatic Encephalopathy in Cirrhosis SYMPOSIUM Session 2 : Cholestatic Liver 09:45-10:15 Session 2: Viral Hepatitis C- Challenges Disease - Pathophysiology of in Treatment of HCV Infection cholestasis and cholestatic liver 08:00-10:00 Session 1: Cholestatic disorders of childhood Session 1: Kidney Dysfunction in Liver Failure Session 2: Nutrition and Coagulation in Liver Failure 10:45-11:55 Session 3: NAFLD- NAFLD as a Systemic Disease 10:45-11:50 Session 3 : Liver Failure 10:15-10:45 + Poster rounds 10:30-12:10 Session 2: Portal Session 2: Advances in Hypertension, Pediatric Liver Diseases coagulation and Variceal Bleed- Screening, Session 3 :Septic shock in Liver prophylaxis and Failure management of bleeding in Liver 16th March, 11:55-13:15 11:55-13.15 Session 4: Liver Fibrosis- Pathogenesis Session 4: Musculoskeletal of liver fibrosis disorders in chronic liver disease 12:00-13.15 Session 3: Hepatocellular Session 3: Non-cirrhotic carcinoma -PathogenesisPortal hypertension and diagnosis of HCC 12: 00-13:15 Session 4: Brain and Heart in Sepsis in Liver Failure Plenary Presentations Young Investigator award presentations (Basic) Session 4: APASL- AASLD Symposium on Alcoholic Liver Disease Oral Paper Poster round + Symposia Session 5: Pulmonary Dysfunction in liver failure 16:50-17:55 Session 5: Alcoholic liver disease- Global Alliance on Alcoholic Liver Disease (GLAD) 17:15-18:15 Session 5: Drug Forum: 15:30-16:30 15:45-16:30 Session 4: Metabolic Live Session 6: Case scenarios in critical care hepatology-1 16:30-16:50 Coffee break+ Poster rounds 17:00-17:45 Session 5:Cholestatic Session 5: Liver Session 7 : Case scenarios in Liver Disease - Diagnosis Transplantation in Critical care Hepatology and Management of childhood Cholestatic liver 18:15-19:15 Evening Symposium Dinner 20:30- Onwards

17 th March, Liver Pathology Symposium and Radiology Session Nutrition in liver APASLINASL Symposium Hepatovirology Oral papers Oral papers Oral papers 08:30-09:30 Session 1: Alcoholic liver disease- Session 1: Hepatic Session 1: Liver Patholog Session 1: Nutritional Global Alliance on Alcoholic Liver regenerative medicine- Nontransplant approaches in a Liver Pathology Update/ Advances in Assessment in cirrhosis Disease (GLAD) 08:00-10:00hrs failing liver Session 1: APASL-EASL Symposium : What I do 09:30-10:30 09:10-10:20 not know about chronic Session 2: Hepatic Session 2: Liver fibrosis Session 2 : Nutritional hepatitis B virus infectio Encephalopathy- Hepatic interventions in Cirrhotic with Session 2: Viral hepatitis C- HCV Encephalopathy in Acute Liver Failure replication and co-infections Liver failure and Acute on Chronic Liver Failure 10:15-10:45 + Poster rounds 10:45-12:10 11:00-12:00 Session 3: NAFLD- Pathogenesis, Session 3: Autoimmune Live Session 3: Liver tumors- Session 3:Nutrition in Liver Epidemiology and Natural History of Disorders- Pathogenesis and update Failure NAFLD Diagnosis of Autoimmune Liver Disorders Session 4: Liver immunology and inflammation 11:15:-12:15 12:00-13:00 12: 00-13:15 Session: Hepatocellular Session 4: Liver transplan APASL INASL Symposium carcinoma -Staging and pathology-1 Management of HCC Session 4: Mixed and rare Liver Tumors-Diagnosis and Management 17th March, + Symposium 14:30-15:00 Plenary Presentations Young Investigator award presentations (Clinical) 14:30-15:15 Session 1: Liver imaging Session 1: Hepato-Virology Symposium: Viral Hepatitis Testing: way forward 15:00-16:30 Plenary Presentations (Basic) State of the art(world Gastroenterology Organization ) lecture 15:15-16:00 Session 2: Interventional Radiology in Portal Hypertension 16:30-17:00 Coffee break+ Poster rounds

18 th March, Session 5: Viral hepatitis B-Newer therapies for cure of Hepatitis B Session 6: Portal Hypertension, Coagulation and Variceal Bleed- 16:30-17:15 Session 3: Intervention Radiology in Liver Tumours 16:30-18:00 Session 2: Viral infections in Solid organ transplants Coagulation, thrombosis and vascular Liver Diseases 17:15-18:00 Session 4: Intervention Radiology in post transplant and biliary system 18:15-19:15 Evening Symposium APASL-INASL Symposium Endoscopy in liver : Theme-Challanges for advanced endoscopy in liver Oral papers Oral papers Oral papers Session 1: Viral hepatitis B- HBV in special situations 08:00-10:00 08:00-10:15 Session 1: Portal Session 1: Alcohol, Session 1: Liver Clinic (10 Session 1: GI endoscopy in Hypertension, Coagulation Obesity and Liver Cancer and Variceal Bleed- Challenges in coagulation an vascular of liver cases can be selected) patients with liver Session 2: Autoimmune liver DisordeSession 2: Alcoholic Liver Management of Autoimmune Liver Disease- Management of Disorders Severe Alcoholic Hepatitis Session: Iron in Liver 18 th March, Session 3: Hepatocellular carcinoma - Novel Therapeutic targets for HCC 11:15-11:45 12:00-13:00 Session 4: Drug Induced Liver Injury- Spectrum of DILI 10:15-10:45 Session 2: Biliary interventions Session 2: INASL Clinical in portal hypertension Practice Guidelines 10:15-12:00 12: 15-13:15 Session 3: Bile acids and Session 3: Endoscopic Session 3: APASL-INASL Liver Aisease management of obesity in liver CPC [Case from PGI] 11:45-13:00 Session 3: Hepatic regenerative medicine- Cell therapies in Liver Diseases Session 4: Frontiers in Liver Disease Symposium + Poster Rounds Session 4: EUS in portal hypertension- why, when and how?